DFCI Logo
DFCI Logo
Steven P. Treon, MD, PhD

Steven P. Treon, MD, PhD

Medical Oncology
MAKE AN APPOINTMENT

Contact Information

Office Phone Number

617-632-4218

Fax

617-632-4862

On This Page

Biography

Steven P. Treon, MD, PhD

Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia Research and an attending physician for medical oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group. After earning a doctorate in tumor immunology from Boston University (BU), Dr. Treon did a postgraduate fellowship in the Department of Microbiology at BU School of Medicine. Dr. Treon received a medical degree from BU School of Medicine and completed an internship in medicine and a residency in internal medicine at BU Medical Center. Dr. Treon also served a clinical fellowship in hematology and oncology at Mass. General Hospital and a research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine in 1995, and in medical oncology in 1997. Dr. Treon's main research interests focus on understanding the genetic basis and pathogenesis of Waldenström's macroglobulinemia and the development of therapeutics for this malignancy. He serves on the editorial boards of the Journal of Clinical Oncology, Blood, Clinical Cancer Research, and The Lancet. Dr Treon is a member of several professional societies, including the American Medical Association, American Society of Hematology, American Society of Clinical Oncology, European Society of Hematology and the Massachusetts Medical Society. He has been honored with several research and academic awards from various national and international medical foundations and institutes, including the Robert A. Kyle Award for Waldenström's Macroglobulinemia.

Researcher

Physician

Director, Bing Center for Waldenström's Macroglobulinemia
Senior Physician
Professor of Medicine, Harvard Medical School

Centers/Programs

Waldenström’s Macroglobulinemia
Stem Cell Transplantation

Clinical Interests

Waldenström’s Macroglobulinemia

Diseases Treated

Board Certification

  • Medical Oncology, 1997

Fellowship

  • Massachusetts General Hospital, Hematology & Oncology

Residency

  • Boston University Medical Center, Internal Medicine

Medical School

  • Boston University School of Medicine

Research

    View Dr. Treon’s Research

    Immunotherapy of Plasma Cell Dyscrasias

    Our research has focused on understanding the genetic basis and pathogenesis of Waldenström's macroglobulinemia (WM) and on developing therapeutics for this B cell malignancy, which affects 6,000 to 10,000 patients a year in the United States. As part of our efforts, we recently characterized a familial form of WM, describing its incidence and clinical, laboratory, and cytogenetic characteristics. Importantly, we also demonstrated differing patterns of gene losses among WM patients, including the genes BLIMP1, PAX5, and members of the unfolded protein response (UPR), including XBP1 and IRE1a. Our studies have also provided important insight into the pathogenesis of WM by demonstrating a role for the excess mast cells found in the bone marrow of patients with WM. We recently demonstrated that mast cells serve as potent inducers of growth and enhancers of tumor cell survival through a host of mediators including CD40 ligand, a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (B-LYS) protein, platelet-derived growth factor (PDGF alpha), and vascular endothelial growth factor (VEGF). At the same time, we showed that WM tumor cells induce expression of several of these ligands through soluble CD27. These discoveries have helped in the development of novel therapeutic strategies targeting mast cells and mast cell-tumor cell interactions in WM. In other studies, we have sought to advance the therapy for WM by conducting clinical trials utilizing monoclonal antibodies as single agents and in combination with nucleoside analogs, cytotoxic agents, and immunomodulating agents, as well as phosphodiesterase and proteasome inhibitors. As part of this work, our lab has defined the mechanisms of action and resistance for these agents, specifically the role of Fc gamma receptor polymorphisms in predicting clinical responses to the CD20-directed monoclonal antibody rituximab. This work has resulted in several novel agents for treating WM, and ongoing clinical trials are evaluating their efficacy and toxicity.

    Research Departments

    Support my research

    Publications

      View Dr. Treon's Publications

      • Reply to Y. Song et al. J Clin Oncol. 2023 Dec 04; JCO2302162. View in: Pubmed

      • Ibrutinib and venetoclax as primary therapy in symptomatic treatment naïve Waldenström macroglobulinemia. Blood. 2023 Oct 27. View in: Pubmed

      • Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023 Nov 20; 41(33):5099-5106. View in: Pubmed

      • Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenström's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060. View in: Pubmed

      • Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care. Semin Hematol. 2023 Mar; 60(2):59-64. View in: Pubmed

      • Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Semin Hematol. 2023 Mar; 60(2):97-106. View in: Pubmed

      • Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia. Semin Hematol. 2023 Mar; 60(2):90-96. View in: Pubmed

      • Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis. Semin Hematol. 2023 Mar; 60(2):113-117. View in: Pubmed

      • Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. Semin Hematol. 2023 Mar; 60(2):73-79. View in: Pubmed

      • Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management. Semin Hematol. 2023 Mar; 60(2):107-112. View in: Pubmed

      • Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients. Semin Hematol. 2023 Mar; 60(2):80-89. View in: Pubmed

      • Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials. Semin Hematol. 2023 Mar; 60(2):118-124. View in: Pubmed

      • Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia. Future Oncol. 2023 Feb; 19(5):345-353. View in: Pubmed

      • Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2023 06; 201(5):897-904. View in: Pubmed

      • Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. Am J Hematol. 2023 02; 98(2):338-347. View in: Pubmed

      • Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia. Int J Cancer. 2023 05 01; 152(9):1947-1963. View in: Pubmed

      • Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022 11 24; 140(21):2193-2227. View in: Pubmed

      • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 09 15; 140(11):1229-1253. View in: Pubmed

      • High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Adv. 2022 06 28; 6(12):3655-3658. View in: Pubmed

      • A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 06 14; 6(11):3332-3338. View in: Pubmed

      • A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib. EJHaem. 2022 Aug; 3(3):927-929. View in: Pubmed

      • Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2022 05 01; 107(5):1163-1171. View in: Pubmed

      • Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Rev Anticancer Ther. 2022 05; 22(5):471-478. View in: Pubmed

      • Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2022 04 12; 6(7):2230-2235. View in: Pubmed

      • Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. Open Forum Infect Dis. 2022 May; 9(5):ofac104. View in: Pubmed

      • SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):547-556. View in: Pubmed

      • Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022 02 08; 6(3):1015-1024. View in: Pubmed

      • Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1. Front Immunol. 2021; 12:790258. View in: Pubmed

      • IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021 11 18; 138(20):1980-1985. View in: Pubmed

      • Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71. View in: Pubmed

      • Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021 11 18; 138(20):2002-2005. View in: Pubmed

      • The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 11 18; 138(20):1966-1979. View in: Pubmed

      • A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica. 2021 11 01; 106(11):2940-2946. View in: Pubmed

      • Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. Blood. 2021 10 28; 138(17):1535-1539. View in: Pubmed

      • Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2022 01 01; 40(1):52-62. View in: Pubmed

      • Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539. View in: Pubmed

      • How to Sequence Therapies in Waldenström Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92. View in: Pubmed

      • Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial. Clin Cancer Res. 2021 11 01; 27(21):5793-5800. View in: Pubmed

      • Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468. View in: Pubmed

      • Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. Hemasphere. 2021 Aug; 5(8):e624. View in: Pubmed

      • Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253. View in: Pubmed

      • Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021 08; 194(4):730-733. View in: Pubmed

      • Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676. View in: Pubmed

      • Clinical application of genomics in Waldenström macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815. View in: Pubmed

      • Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics. 2021 01; 13(2):129-144. View in: Pubmed

      • Management of Waldenström macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379. View in: Pubmed

      • CXCR4 in Waldenström's Macroglobulinema: chances and challenges. Leukemia. 2021 02; 35(2):333-345. View in: Pubmed

      • Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550. View in: Pubmed

      • Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837. View in: Pubmed

      • The race to stymie BTK: zanu zings. Blood. 2020 10 29; 136(18):1997-1999. View in: Pubmed

      • Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Adv. 2020 10 27; 4(20):5089-5092. View in: Pubmed

      • Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Med Chem Lett. 2020 Nov 12; 11(11):2238-2243. View in: Pubmed

      • Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia. Blood Adv. 2020 09 22; 4(18):4550-4553. View in: Pubmed

      • Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575. View in: Pubmed

      • Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959. View in: Pubmed

      • Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Aug; 4(4):e433. View in: Pubmed

      • Epigenomics in Waldenström macroglobulinemia. Blood. 2020 07 30; 136(5):527-529. View in: Pubmed

      • Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. Hemasphere. 2020 Jun; 4(3):e363. View in: Pubmed

      • The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915. View in: Pubmed

      • Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170. View in: Pubmed

      • Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208. View in: Pubmed

      • SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12. View in: Pubmed

      • A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Leuk Lymphoma. 2020 06; 61(6):1388-1394. View in: Pubmed

      • CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98. View in: Pubmed

      • Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Adv. 2020 01 14; 4(1):141-153. View in: Pubmed

      • Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378. View in: Pubmed

      • Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. J Am Acad Dermatol. 2023 06; 88(6):1271-1281. View in: Pubmed

      • Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019 11 12; 3(21):3360-3374. View in: Pubmed

      • CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. Blood Adv. 2019 10 08; 3(19):2800-2803. View in: Pubmed

      • What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562. View in: Pubmed

      • How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285. View in: Pubmed

      • Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702. View in: Pubmed

      • Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 Aug 01; 25(15):4860. View in: Pubmed

      • CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881. View in: Pubmed

      • CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363. View in: Pubmed

      • Genomic landscape of Waldenström's macroglobulinemia. Hemasphere. 2019 Jun; 3(Suppl). View in: Pubmed

      • Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411. View in: Pubmed

      • Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019 02 28; 133(9):952-961. View in: Pubmed

      • Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305. View in: Pubmed

      • Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 02; 184(4):558-569. View in: Pubmed

      • Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790. View in: Pubmed

      • Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946. View in: Pubmed

      • Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802. View in: Pubmed

      • Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612. View in: Pubmed

      • Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018; 13(10):e0204589. View in: Pubmed

      • Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematol Oncol Clin North Am. 2018 10; 32(5):xiii-xiv. View in: Pubmed

      • Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):369-377. View in: Pubmed

      • TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245. View in: Pubmed

      • Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res. 2018 12 15; 24(24):6408-6420. View in: Pubmed

      • Genomic Landscape of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752. View in: Pubmed

      • Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761. View in: Pubmed

      • Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):811-820. View in: Pubmed

      • The real world of Waldenström's macroglobulinaemia. Lancet Haematol. 2018 07; 5(7):e275-e276. View in: Pubmed

      • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Jun 21; 378(25):2399-2410. View in: Pubmed

      • Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468. View in: Pubmed

      • Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia. Am J Hematol. 2018 May 14. View in: Pubmed

      • Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. JAMA Oncol. 2018 05 01; 4(5):744-745. View in: Pubmed

      • Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. Clin Cancer Res. 2018 07 15; 24(14):3247-3252. View in: Pubmed

      • MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018 09; 103(9):e408-e411. View in: Pubmed

      • Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014. View in: Pubmed

      • BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018 05 03; 131(18):2047-2059. View in: Pubmed

      • Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85. View in: Pubmed

      • Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310. View in: Pubmed

      • Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517. View in: Pubmed

      • Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. Blood. 2018 04 12; 131(15):1720-1729. View in: Pubmed

      • Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71. View in: Pubmed

      • Toward personalized treatment in Waldenström macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370. View in: Pubmed

      • What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Adv. 2017 Nov 28; 1(25):2486-2490. View in: Pubmed

      • MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 02; 180(3):374-380. View in: Pubmed

      • A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chem Biol. 2018 01 18; 25(1):88-99.e6. View in: Pubmed

      • CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica. 2017 11; 102(11):e452-e455. View in: Pubmed

      • Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. Br J Haematol. 2017 10; 179(1):106-115. View in: Pubmed

      • Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744. View in: Pubmed

      • The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. Oncotarget. 2017 May 23; 8(21):35435-35444. View in: Pubmed

      • Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725. View in: Pubmed

      • Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology. 2017; 6(7):e1321184. View in: Pubmed

      • Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017 05 04; 129(18):2519-2525. View in: Pubmed

      • Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017 03; 176(5):728-742. View in: Pubmed

      • Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001. View in: Pubmed

      • Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 02; 15(2):230-269. View in: Pubmed

      • Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250. View in: Pubmed

      • Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404. View in: Pubmed

      • MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581. View in: Pubmed

      • Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017 01; 102(1):43-51. View in: Pubmed

      • Epigenomics in Waldenstrom's macroglobulinaemia. Best Pract Res Clin Haematol. 2016 06; 29(2):156-160. View in: Pubmed

      • Future therapeutic options for patients with Waldenström macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215. View in: Pubmed

      • Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004. View in: Pubmed

      • Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. Oncologist. 2016 Nov; 21(11):1377-1386. View in: Pubmed

      • Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630. View in: Pubmed

      • Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5. View in: Pubmed

      • Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 09 08; 128(10):1321-8. View in: Pubmed

      • Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341. View in: Pubmed

      • Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br J Haematol. 2016 10; 175(1):77-86. View in: Pubmed

      • Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016 08 11; 128(6):827-38. View in: Pubmed

      • Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol. 2016 Aug; 7(4):179-86. View in: Pubmed

      • Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109. View in: Pubmed

      • HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52. View in: Pubmed

      • Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3. View in: Pubmed

      • Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813. View in: Pubmed

      • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400. View in: Pubmed

      • Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701. View in: Pubmed

      • To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824. View in: Pubmed

      • Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606. View in: Pubmed

      • Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia. 2016 05; 30(5):1116-25. View in: Pubmed

      • miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016 Jan 15; 6:e380. View in: Pubmed

      • Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9. View in: Pubmed

      • Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15. View in: Pubmed

      • Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44. View in: Pubmed

      • Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia. Haematologica. 2016 Mar; 101(3):e111-5. View in: Pubmed

      • Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clin Cancer Res. 2016 05 01; 22(9):2226-36. View in: Pubmed

      • Rituximab intolerance in patients with Waldenström macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8. View in: Pubmed

      • Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435. View in: Pubmed

      • MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med. 2015 Aug 06; 373(6):584-6. View in: Pubmed

      • Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46. View in: Pubmed

      • Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701. View in: Pubmed

      • The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80. View in: Pubmed

      • How I treat Waldenström macroglobulinemia. Blood. 2015 Aug 06; 126(6):721-32. View in: Pubmed

      • Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3. View in: Pubmed

      • Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40. View in: Pubmed

      • Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. Cancer. 2015 Jul 01; 121(13):2230-6. View in: Pubmed

      • Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clin Cancer Res. 2015 Jun 01; 21(11):2538-45. View in: Pubmed

      • The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8. View in: Pubmed

      • Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95. View in: Pubmed

      • Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr; 169(1):81-9. View in: Pubmed

      • Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4. View in: Pubmed

      • CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7. View in: Pubmed

      • Waldenström macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70. View in: Pubmed

      • Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11. View in: Pubmed

      • Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19; 123(25):3999-4000. View in: Pubmed

      • The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. Leukemia. 2015 Jan; 29(1):169-76. View in: Pubmed

      • Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10. View in: Pubmed

      • Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia. Br J Haematol. 2014 Sep; 166(5):677-89. View in: Pubmed

      • Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91. View in: Pubmed

      • MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014 Apr 24; 123(17):2673-81. View in: Pubmed

      • miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; 74(6):1801-13. View in: Pubmed

      • Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014 Mar; 89(3):237-42. View in: Pubmed

      • Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014 May 01; 123(18):2791-6. View in: Pubmed

      • Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia. 2014 Aug; 28(8):1698-704. View in: Pubmed

      • Waldenström macroglobulinemia: from biology to treatment. Expert Rev Hematol. 2014 Feb; 7(1):157-68. View in: Pubmed

      • The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014 Mar 13; 123(11):1637-46. View in: Pubmed

      • Proteasome inhibitors in Waldenström macroglobulinemia. Blood. 2013 Nov 07; 122(19):3243-4. View in: Pubmed

      • Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome. Genes Immun. 2014 Jan; 15(1):54-6. View in: Pubmed

      • A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013 Aug 15; 122(7):1222-32. View in: Pubmed

      • XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features. Hematol Oncol. 2013 Jun; 31 Suppl 1:76-80. View in: Pubmed

      • A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood. 2013 May 30; 121(22):4434-6. View in: Pubmed

      • Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):181-3. View in: Pubmed

      • Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):247-9. View in: Pubmed

      • Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):250-2. View in: Pubmed

      • Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):241-3. View in: Pubmed

      • microRNA aberrations in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):205-7. View in: Pubmed

      • MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8. View in: Pubmed

      • Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):11-7. View in: Pubmed

      • Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6. View in: Pubmed

      • Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2012 Dec; 12(6):433-7. View in: Pubmed

      • Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1211-9. View in: Pubmed

      • MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012 Aug 30; 367(9):826-33. View in: Pubmed

      • Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87. View in: Pubmed

      • Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther. 2012 Apr; 11(4):942-51. View in: Pubmed

      • Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. Cancer Epidemiol. 2012 Jun; 36(3):294-7. View in: Pubmed

      • Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83. View in: Pubmed

      • Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leuk Lymphoma. 2011 Sep; 52(9):1777-86. View in: Pubmed

      • Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011 Aug; 154(3):357-62. View in: Pubmed

      • Association of familial disease status with inferior treatment outcome in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2011 May 20; 29(15_suppl):8073. View in: Pubmed

      • Site-specific relative risks of second primary malignancies among patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2011 May 20; 29(15_suppl):e18566. View in: Pubmed

      • Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011 Jul 14; 118(2):276-81. View in: Pubmed

      • Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol. 2011 Jul; 154(2):223-8. View in: Pubmed

      • Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):172-5. View in: Pubmed

      • Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):133-5. View in: Pubmed

      • Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):160-3. View in: Pubmed

      • Report from the Sixth International Workshop on Waldenström's Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):68-73. View in: Pubmed

      • Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):152-6. View in: Pubmed

      • Associated malignancies in patients with Waldenström's macroglobulinemia and their kin. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):88-92. View in: Pubmed

      • Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. Blood. 2011 Mar 10; 117(10):2918-23. View in: Pubmed

      • Fc? receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10(5):321-2. View in: Pubmed

      • Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4. View in: Pubmed

      • Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92. View in: Pubmed

      • Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2010 Apr; 10(2):110-7. View in: Pubmed

      • Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14. View in: Pubmed

      • Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8. View in: Pubmed

      • Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4. View in: Pubmed

      • IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica. 2010 Mar; 95(3):470-5. View in: Pubmed

      • How I treat Waldenström macroglobulinemia. Blood. 2009 Sep 17; 114(12):2375-85. View in: Pubmed

      • Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10; 27(23):3830-5. View in: Pubmed

      • Clinical and biological significance of microRNA profiling in patients with myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):8539. View in: Pubmed

      • TNF-a, retinoid acid and STAT4 pathways are differentially regulated by the HDAC inhibitors, SAHA, TSA and Sirtinol in Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):e14582. View in: Pubmed

      • Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar; 9(1):71-3. View in: Pubmed

      • Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):100-3. View in: Pubmed

      • Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):62-6. View in: Pubmed

      • Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):56-8. View in: Pubmed

      • Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma. 2009 Mar; 9(1):10-5. View in: Pubmed

      • Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr; 145(1):59-63. View in: Pubmed

      • International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009 Apr 30; 113(18):4163-70. View in: Pubmed

      • Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60. View in: Pubmed

      • Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10; 27(2):250-5. View in: Pubmed

      • Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 Jan 01; 27(1):120-6. View in: Pubmed

      • Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16; 113(16):3673-8. View in: Pubmed

      • Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15; 113(3):626-34. View in: Pubmed

      • Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. Blood. 2008 Dec 15; 112(13):5111-21. View in: Pubmed

      • Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31. View in: Pubmed

      • Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4452-7. View in: Pubmed

      • The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008 Sep; 142(5):775-85. View in: Pubmed

      • Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008 Jun; 49(6):1104-7. View in: Pubmed

      • Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). J Clin Oncol. 2008 May 20; 26(15_suppl):8546. View in: Pubmed

      • Expression of the deleted in liver cancer-1 gene is regulated by DNA methylation and is a target for therapy in Waldenström's Macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):19505. View in: Pubmed

      • Use of soluble CD27 as a marker of disease burden and the effect of rituximab-induced IgM flare and plasmapheresis in patients with Waldenström's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8585. View in: Pubmed

      • Increased prevalence of monoclonal gammopathy, abnormal immunoglobulin levels, and recurrent infections in family members of patients with familial Waldenstrom's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8540. View in: Pubmed

      • Serum Immunoglobulin free light chains as markers of disease burden and response to treatment in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8617. View in: Pubmed

      • Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008 Mar 15; 14(6):1849-58. View in: Pubmed

      • Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008 May 15; 111(10):5068-77. View in: Pubmed

      • Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. Eur J Haematol. 2008 Jun; 80(6):503-9. View in: Pubmed

      • Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 01; 111(9):4752-63. View in: Pubmed

      • Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. Invest Ophthalmol Vis Sci. 2008 Mar; 49(3):1157-60. View in: Pubmed

      • CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4683-9. View in: Pubmed

      • Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma. Cancer Treat Res. 2008; 142:211-42. View in: Pubmed

      • Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75. View in: Pubmed

      • The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007 Dec 15; 110(13):4417-26. View in: Pubmed

      • Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206. View in: Pubmed

      • Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007 Jun 01; 13(11):3320-5. View in: Pubmed

      • Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007 Oct 01; 110(7):2561-4. View in: Pubmed

      • Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67(8):3777-84. View in: Pubmed

      • Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin Cancer Res. 2007 Apr 01; 13(7):2005-13. View in: Pubmed

      • Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007 Jun 01; 109(11):4964-72. View in: Pubmed

      • Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007 Jan; 82(1):83-4. View in: Pubmed

      • Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007 Jan; 7(4):286-90. View in: Pubmed

      • Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006 Dec 01; 12(23):7174-9. View in: Pubmed

      • Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. Arch Ophthalmol. 2006 Nov; 124(11):1601-6. View in: Pubmed

      • Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10. View in: Pubmed

      • Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7523. View in: Pubmed

      • Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7556. View in: Pubmed

      • Therapeutic targeting of CD70 and CD27-CD70 interactions with the monoclonal antibody SGN-70 in Waldenstrom's Macroglobulinemia (WM). J Clin Oncol. 2006 Jun 20; 24(18_suppl):2509. View in: Pubmed

      • Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006 Aug; 17(8):1275-82. View in: Pubmed

      • Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006 Jul 01; 43(1):16-24. View in: Pubmed

      • CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006 May; 6(6):478-83. View in: Pubmed

      • Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006 Mar; 6(5):380-3. View in: Pubmed

      • Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood. 2006 May 01; 107(9):3442-6. View in: Pubmed

      • Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006 Mar; 17(3):488-94. View in: Pubmed

      • Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20. View in: Pubmed

      • A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood. 2005 Aug 15; 106(4):1341-5. View in: Pubmed

      • Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol. 2005 Mar 01; 23(7):1564-77. View in: Pubmed

      • Report of the Third International Workshop on Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):215-6. View in: Pubmed

      • Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):253-6. View in: Pubmed

      • CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):246-9. View in: Pubmed

      • CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):273-7. View in: Pubmed

      • Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol. 2005 Jan 20; 23(3):474-81. View in: Pubmed

      • Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005 Jan; 16(1):132-8. View in: Pubmed

      • Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203. View in: Pubmed

      • Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2004 Dec; 5(3):205-7. View in: Pubmed

      • Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004 Oct; 15(10):1481-3. View in: Pubmed

      • Polymorphisms in Fc?RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6556. View in: Pubmed

      • Heterogeneous expression of CD5, CD10, and CD23 in Waldenstrom's macroglobulinemia. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6730. View in: Pubmed

      • Excess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6555. View in: Pubmed

      • Characterization of familial Waldenstrom's Macroglobulinemia. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6558. View in: Pubmed

      • Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52. View in: Pubmed

      • Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52. View in: Pubmed

      • Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood. 2004 Oct 01; 104(7):2134-42. View in: Pubmed

      • Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2004; 257-82. View in: Pubmed

      • Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96. View in: Pubmed

      • Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May; 121(4):592-6. View in: Pubmed

      • Defining Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):107-9. View in: Pubmed

      • Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol. 2003 Apr; 30(2):248-52. View in: Pubmed

      • The malignant clone in Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):132-5. View in: Pubmed

      • Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6. View in: Pubmed

      • Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):127-31. View in: Pubmed

      • Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):309-12. View in: Pubmed

      • Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol. 2003 Apr; 30(2):156-60. View in: Pubmed

      • Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):110-5. View in: Pubmed

      • Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):116-20. View in: Pubmed

      • CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003 Apr 01; 101(7):2762-9. View in: Pubmed

      • Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9. View in: Pubmed

      • Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83. View in: Pubmed

      • Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30. View in: Pubmed

      • Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86. View in: Pubmed

      • Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 2002 Mar 15; 99(6):2162-71. View in: Pubmed

      • CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002 Jan-Feb; 25(1):72-81. View in: Pubmed

      • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001 Dec; 15(12):1950-61. View in: Pubmed

      • TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001 Aug 01; 98(3):795-804. View in: Pubmed

      • Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs. 2001 Aug; 10(8):1521-30. View in: Pubmed

      • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 01; 98(1):210-6. View in: Pubmed

      • Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J Immunother (1991). 2001 May; 24(3):263-271. View in: Pubmed

      • CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother. 2001 May-Jun; 24(3):272-9. View in: Pubmed

      • Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001 May-Jun; 24(3):263-71. View in: Pubmed

      • CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991). 2001 May; 24(3):272-279. View in: Pubmed

      • Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol. 2000 Dec 01; 165(11):6347-55. View in: Pubmed

      • The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000 Dec; 27(6 Suppl 12):79-85. View in: Pubmed

      • Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 2000 Nov 01; 96(9):3147-53. View in: Pubmed

      • Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000 Nov 01; 96(9):2943-50. View in: Pubmed

      • Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol. 2000 Oct; 27(5):598-613. View in: Pubmed

      • SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000 Sep 08; 275(36):27845-50. View in: Pubmed

      • Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid. 2000 Jun; 7(2):126-32. View in: Pubmed

      • Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res. 2000 Mar; 6(3):1180-9. View in: Pubmed

      • Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods. 2000 Feb 21; 235(1-2):11-9. View in: Pubmed

      • CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood. 2000 Feb 01; 95(3):1039-46. View in: Pubmed

      • Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol. 2000; 11 Suppl 1:107-11. View in: Pubmed

      • RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999 Nov 18; 18(48):6733-40. View in: Pubmed

      • Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol. 1999 Oct; 26(5 Suppl 14):97-106. View in: Pubmed

      • Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. Cancer Res. 1999 Mar 15; 59(6):1192-5. View in: Pubmed

      • Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999 Mar 01; 93(5):1487-95. View in: Pubmed

      • Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood. 1999 Mar 01; 93(5):1482-6. View in: Pubmed

      • Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999 Feb 15; 93(4):1287-98. View in: Pubmed

      • Anti-estrogens induce apoptosis of multiple myeloma cells. Blood. 1998 Sep 01; 92(5):1749-57. View in: Pubmed

      • The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest. 1998 Mar 15; 101(6):1379-88. View in: Pubmed

      • Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol. 1998 Jan; 5(1):42-8. View in: Pubmed

      • p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. Blood. 1997 Nov 15; 90(10):4106-15. View in: Pubmed

      • Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. Leukemia. 1997 Nov; 11(11):1957-63. View in: Pubmed

      • Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res. 1997 Nov; 3(11):2173-9. View in: Pubmed

      • MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 1997 Sep 01; 90(5):1982-92. View in: Pubmed

      • IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997 Sep 01; 159(5):2212-21. View in: Pubmed

      • Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 1997 Aug 14; 15(7):837-43. View in: Pubmed

      • The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997 Jul 15; 90(2):754-65. View in: Pubmed

      • Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood. 1997 Jul 01; 90(1):279-89. View in: Pubmed

      • Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res. 1997 Jun; 3(6):1017-22. View in: Pubmed

      • Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996 Aug; 42(8 Pt 2):1322-9. View in: Pubmed

      • CD14 mediated endogenous TNF-alpha release in HL60 AML cells: a potential model for CD14 mediated endogenous cytokine release in the treatment of AML. Leuk Res. 1994 Jan; 18(1):17-21. View in: Pubmed

      • Lipopolysaccharide (LPS) processing by Kupffer cells releases a modified LPS with increased hepatocyte binding and decreased tumor necrosis factor-alpha stimulatory capacity. Proc Soc Exp Biol Med. 1993 Feb; 202(2):153-8. View in: Pubmed

      • Monoclonal antibody therapy in the treatment of Reye's syndrome. Med Hypotheses. 1992 Nov; 39(3):238-42. View in: Pubmed

      • Beneficial effects of post-transfusional hepatitis in acute myelogenous leukemia may be mediated by lipopolysaccharides, tumor necrosis factor alpha and interferon gamma. Leukemia. 1992 Oct; 6(10):1036-42. View in: Pubmed

      • Growth restraint and differentiation by LPS/TNF-alpha/IFN-gamma reorganization of the microtubule network in human leukemia cell lines. Leukemia. 1992; 6 Suppl 3:141S-145S. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Mayer 548B Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Mayer 548B Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Steven P. Treon, MD, PhD

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights

      Back to Top